TJ-114 (Sai)

✓ Approved

什么是 TJ-114？

TJ-114 是一种治疗药物，由Tsumura研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名	Sai
公司	Tsumura
分子靶点	IL1RN
给药途径	Oral (PO)
状态	Approved

来源： ClinicalTrials.gov, Tsumura

作用机制

分子靶点

TJ-114 作用于 1 个分子靶点：

IL1RN

interleukin 1 receptor antagonist (IL1F3, IL-1RN)

需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

TJ-114 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域	疾病/病症	分期
Renal and urinary disorders	Nephritis	✓ Approved

相关研究文献

PubMedBioscience, biotechnology, and biochemistry2026-09-10

Exploratory analysis of the associations of short-chain fatty acids and their related factors with growth performance in growing pigs using a Bayesian network.

Takahashi Toru T, Tsukahara Takamitsu T, Miura Hiroto H, Kawase Takahiro T et al.

We suggested the causal relationships between daily weight gains (DG) and feed conversion ratios (FCR) of growing pigs, and short-chain fatty acids (SCFA) concentrations in digesta and blood, and SCFA-related factors such as intestinal morphology, SCFA transporters and tight junction (TJ) proteins. Twelve pigs were divided into 5% of rapeseed meal-, beet pulp- or starch-supplemented groups, kept for 21 days, and dissected. Bayesian network showed that factors affecting DG were expressions of sodium-coupled monocarboxylate transporter 1, claudin-1, and Zonula occludens-1 in cecal mucosa, monocarboxylate transporter 1 and occludin in ileal mucosa, and SCFA concentrations in abdominal aortas. Factors affecting FCR were type of diet, villous height in ileum, SCFA concentrations in ileal veins and cecal digesta. Greater DG may be associated with stimulation of SCFA transportation and regulation of TJ functions, whereas reduced FCR appears to be linked to villous elongation and stimulation of SCFA production in the intestine.

PMID 42720415

阅读全文 →

PubMedClinical toxicology (Philadelphia, Pa.)2026-09-10

Evaluating clinical characteristics and outcomes associated with body stuffers presenting to the emergency department: a five-year retrospective analysis from a United States poison center.

Vohra Varun V, Rabotnick Joshua J, Rabotnick Margaret H MH, King Andrew A

"Body stuffing" refers to the ingestion of illicit drugs, often to evade law enforcement or prosecution. Management presents a clinical challenge, often centered around determining appropriate observation duration for asymptomatic or symptomatically resolved patients. To better guide clinical decision-making, this study aims to evaluate clinical characteristics, outcomes, and the efficacy of an often-implemented monitoring duration associated with body stuffers. We performed a five-year retrospective analysis of body stuffing cases reported to a single United States poison center from 1 January 2019 to 31 December 2023. All ages and sexes were included. Non-ingestion routes and cases where emergency department care was not pursued were excluded. Outcomes included time to new symptom onset and development of new symptoms after emergency department presentation, frequency of symptoms, specific drug(s) and drug wrapping details, and hospital length of stay. Categorical variables were summarized as frequencies and percentages and continuous variables used the median and interquartile range (IQR). Ninety-four cases were included for final analysis. Most cases involved males (70/94, 74.5%) and most (39/67, 58.2%) involved patient observation and monitoring in the emergency department for ≤ 6 hours. Wrappers consisted mainly of plastic or cellophane (74/114, 64.9%). Opioids were most frequently ingested (56/114, 49.1%). Patients were symptomatic in 57/94 (60.6%) of cases. New symptoms developed in 12/94 (12.8%) of patients after initial emergency department presentation, with only 2/94 (2.1%) previously asymptomatic patients developing symptoms >6 hours after emergency department presentation. This study supports the six hour observation period, with some exceptions. Case outliers underscore the limitations of a six hour observation period and the need for clinical judgement in body stuffer cases. Most body stuffers do not develop new or progressive symptoms after presentation within six hours, supporting but not definitively validating the commonly recommended six hour observation time. A modified observation period may be warranted in certain cases.

PMID 42720310

阅读全文 →

PubMedJournal of industrial microbiology & biotechnology2026-09-10

A Survey of Burkholderiales Secondary Metabolites Using Library-Scale Stable Isotope Labeling Reveals Selective Production of Methyl-Esterified 3-Hydroxybutyrate Oligomers.

Zaroubi Liana L, Heard Stephanie C SC, Sutherland Matthew M, Eustaquio Alessandra S AS et al.

Large-scale untargeted bacterial metabolomics studies are often challenging to interpret, particularly for natural product discovery. Complex raw mass spectrometry data contains media components, biotransformation products, workup contaminants, and in-source fragments, making it difficult to resolve true biosynthesized bacterial products from background features. Incorporating stable isotope labels into untargeted workflows enables the selective detection of actively biosynthesized compounds, drastically reducing candidate mass spectrometry features to highlight novel or robustly expressed metabolites. Recently, our lab introduced IsoAnalyst, a parallel stable isotope labeling platform that links secondary metabolites to biosynthetic gene clusters by determining the incorporation rates of a panel of isotopically labeled building blocks. In this study we applied the IsoAnalyst protocol to a library of 114 Burkholderiales strains with the goals of profiling the specialized metabolite chemistry of this bacterial order and connecting detected natural products to their cognate BGCs based on their labeling profiles. While our strain-matching protocol, which evaluates correlations between detected metabolites and BiG-SCAPE-defined gene cluster families, did not yield confident BGC assignments, it successfully highlighted widely distributed metabolites with distinct labeling profiles. We targeted a set of these molecules for isolation, revealing two classes of compounds derived from primary biomolecule metabolism that are implicated in cellular stress responses. The first class of molecules were identified as lysophosphatidyl ethanolamine analogues while the second was characterized via NMR spectroscopy and mass spectrometry as methyl-esterified 3-hydroxybutyrate oligomers (HB6-OMe, HB7-OMe, and HB8-OMe), representing higher-degree polymer units than previously reported.

PMID 42720419

阅读全文 →

PubMedFrontiers in oncology2026-09-10

Comparative evaluation of TACE-RFA versus monotherapies on a background of systemic therapy for recurrent hepatocellular carcinoma: a propensity score-matched analysis.

Zhang Wendi W, Ye Zuhao Z, Wang Jinfa J, Ren Xia X et al.

The optimal locoregional treatment for recurrent hepatocellular carcinoma (rHCC) in the era of potent systemic therapy remains undefined. This study aimed to compare the efficacy, safety, and resource consumption of transarterial chemoembolization combined with radiofrequency ablation (TACE-RFA) versus TACE or RFA monotherapy, specifically when administered on a uniform background of systemic therapy (Lenvatinib plus PD-1 inhibitors). We retrospectively reviewed 243 patients with rHCC who met strict eligibility criteria (tumor size 3.0-7.0 cm, ≤3 recurrent nodules, and preserved liver function, corresponding to Barcelona Clinic Liver Cancer (BCLC) A/B and China Liver Cancer (CNLC) Ia-IIa stages. Crucially, all included patients uniformly received standardized peri-procedural systemic therapy (Lenvatinib and Tislelizumab). Based on the actual locoregional strategies, the cohort was divided into TACE-RFA (n=56), TACE alone (n=114), or RFA alone (n=73) groups. To mitigate selection bias, 1:1 propensity score matching (PSM) was employed, generating two matched cohorts: Combination vs. TACE alone (54 pairs) and Combination vs. RFA alone (54 pairs). Survival outcomes, post-procedural pain, hospital stay, and costs were evaluated. After PSM, baseline characteristics were well-balanced. The median progression-free survival (PFS) in the combination group was 21.4 months, significantly superior to the matched TACE monotherapy cohort (13.5 months, P < 0.001) and the independently matched RFA monotherapy cohort (10.4 months, P < 0.001). Overall survival (OS) showed no significant differences among the groups (median OS 48.9-50.5 months, all P > 0.05), likely because the uniform administration of potent systemic therapy drastically prolonged the baseline survival for all patients, thereby diluting the OS advantage of local control. Safety profiles were comparable across all modalities (P > 0.05). Predictably, combination therapy incurred longer median hospital stays and higher total costs compared to monotherapies (all P < 0.001). For rHCC patients receiving concurrent Lenvatinib and PD-1 inhibitors, sequential TACE-RFA therapy provides a profound and independent progression-free survival benefit over locoregional monotherapies without increasing patient discomfort. The superior local tumor control justifies the anticipated initial increases in perioperative resource consumption.

PMID 42718551

阅读全文 →

PubMedClinical medicine insights. Endocrinology and diabetes2026-09-10

Efficacy and Safety of an Insulin Patch Pump Compared to Multiple Daily Injections in Pediatric Patients With Diabetes: A Randomized, Open-Label, Crossover, Non-Inferiority Clinical Trial.

Fu Junfen J, Wu Jin J, Hui Yao Y, Zhu Weiwei W et al.

Insulin patch pumps offer advantages over multiple daily injections (MDI) for pediatric diabetes, but randomized trial evidence in Chinese children remains limited. To evaluate the efficacy and safety of a tubeless insulin patch pump (Equil™) compared with MDI in children and adolescents with diabetes. This multicenter, open-label, randomized, crossover, non-inferiority trial was conducted at seven pediatric endocrinology centers in China (September 2021 - October 2022). Patients aged 3-17 years with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) were randomized 1:1 to receive continuous subcutaneous insulin infusion (CSII) via Equil™ or MDI via insulin pen for 5 days, followed by crossover. The primary outcome was mean blood glucose (MBG). Non-inferiority margin was pre-specified as 0.386 mmol/L. Secondary outcomes included glycemic variability (standard deviation of blood glucose, SDBG), glycated albumin (GA), total daily insulin dose (TDD), hypoglycemia frequency, and adverse events. Patient satisfaction was assessed using a study-specific 11-item questionnaire. Of 74 enrolled patients, 72 (97.3%) completed the study. CSII demonstrated non-inferiority to MDI for MBG (8.43±1.88 mmol/L, n=74, vs 9.00±2.04 mmol/L, n=72); mean difference -0.606 mmol/L; 95% CI -0.988 to -0.223; upper CI limit -0.223 < non-inferiority margin 0.386. No significant differences were observed for secondary outcomes (SDBG: 3.019 vs 3.357; GA change: 2.52±3.03% vs 2.02±3.25%, p=0.184; TDD: 132.17±78.43 vs 147.52±91.59 IU, p=0.159; hypoglycemia events: 114 vs 106). Adverse event rates were similar (75.7% vs 69.4%, p=0.399); no serious adverse events occurred. Patient satisfaction was significantly higher with CSII (total score 21.03±4.47 vs 22.00±3.99; mean difference -0.97, 95% CI -1.75 to -0.19; p=0.015), with 68.1% of patients preferring the patch pump. The Equil™ patch pump is non-inferior to MDI in terms of glycemic control and safety for pediatric diabetes patients, with higher patient satisfaction. These findings support the patch pump as an effective alternative for children and adolescents requiring exogenous insulin therapy.

PMID 42719483

阅读全文 →

PubMedNeuroendocrinology2026-09-09

Comment on "Congenital Hypogonadotropic Hypogonadism with Anosmia and Gorlin Features Caused by a PTCH1 Mutation Reveals a New Candidate Gene for Kallmann Syndrome" (Barraud et al., Neuroendocrinology, 2021;111:99-114).

Hercent Agathe A, Tchernitchko Dimitri D

PMID 42715142

阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

TJ-114 (Sai)

什么是 TJ-114？

药物档案

作用机制

分子靶点

治疗适应症

相关研究文献

Exploratory analysis of the associations of short-chain fatty acids and their related factors with growth performance in growing pigs using a Bayesian network.

Evaluating clinical characteristics and outcomes associated with body stuffers presenting to the emergency department: a five-year retrospective analysis from a United States poison center.

A Survey of Burkholderiales Secondary Metabolites Using Library-Scale Stable Isotope Labeling Reveals Selective Production of Methyl-Esterified 3-Hydroxybutyrate Oligomers.

Comparative evaluation of TACE-RFA versus monotherapies on a background of systemic therapy for recurrent hepatocellular carcinoma: a propensity score-matched analysis.

Efficacy and Safety of an Insulin Patch Pump Compared to Multiple Daily Injections in Pediatric Patients With Diabetes: A Randomized, Open-Label, Crossover, Non-Inferiority Clinical Trial.

Comment on "Congenital Hypogonadotropic Hypogonadism with Anosmia and Gorlin Features Caused by a PTCH1 Mutation Reveals a New Candidate Gene for Kallmann Syndrome" (Barraud et al., Neuroendocrinology, 2021;111:99-114).

了解更多TJ-114